Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Compared to other racial and ethnic groups, Blacks are also less likely to be diagnosed early.
Treatment with Tecentriq plus Avastin or with Keytruda alone delays disease progression and improves survival.
Areas with lower population density have not seen the same slowdown as urban areas.
Readily available clinical parameters can identify those at greatest risk for hepatocellular carcinoma.
October is Liver Cancer Awareness Month.
Many people with fatty liver disease have obesity, diabetes and other metabolic conditions.
Rates of liver complications were similar, but HIV-positive people had more non-liver cancers and non-liver-related deaths.
Stivarga also improved survival in those with recurrent HCC after a liver transplant.
Liver complications, heart disease and non-liver cancers also account for most deaths among people with hepatitis B or C.
Nearly half of patients treated with the combination saw their tumors shrink in an early study.
NAFLD is the leading indicator of mortality among Medicare beneficiaries with hepatocellular carcinoma.
The regulatory agency requested further data to show whether its benefits outweigh its risks.
This new test could “play an important role” in screening people who are at risk for developing hepatocellular carcinoma.
The combination improved both overall survival and patient-reported outcomes.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.